Anti ICAM-1 (CD 54) monoclonal antibody reduces inflammatory changes in experimental bacterial meningitis.
We investigated whether monoclonal antibodies directed against intracellular adhesion molecule 1 (ICAM-1 mAb) inhibit brain edema, increase of intracranial pressure (ICP), regional cerebral blood flow (rCBF) and recruitment of white blood cells (WBC) into the cerebrospinal fluid (CSF) in the rat model of the early phase of bacterial meningitis. Brain edema was assessed by brain water content determinations. rCBF measured by laser Doppler flowmetry and ICP were recorded continuously for 6 h after intracisternal challenge. Meningitis was induced with pneumococcal cell walls (PCW). Increase of ICP and brain water content were significantly inhibited (P <0.05) by intravenous treatment with ICAM-1 mAb (TM-8, 1 mg/kg). Furthermore, ICAM-1 mAb treatment profoundly attenuated (P <0.05) rCBF increase and WBC invasion into the CSF. These results suggest that the ICAM-1 pathway is critically involved in the early phase of bacterial meningitis.
Weber
J R
JR
Department of Neurology, Universitätsklinikum Charité, Humboldt University Berlin, Germany.
Angstwurm
K
K
Bürger
W
W
Einhäupl
K M
KM
Dirnagl
U
U
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002560:Cerebrovascular Circulation; D018799:Intercellular Adhesion Molecule-1 / Q000502:physiology*; D007427:Intracranial Pressure; D008297:Male; D016920:Meningitis, Bacterial / Q000503:physiopathology / Q000628:therapy*; D051381:Rats; D017208:Rats, Wistar
D000911:Antibodies, Monoclonal; D018799:Intercellular Adhesion Molecule-1